Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.57 |
| ▸ | HPGD | P15428 | 6/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14289389 | 1.00 | SMN1; SMN2 (0.59) | SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL8272416 | 0.87 | MAPK1 (0.53) | SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL5105437 | 0.87 | MAPK1 (0.53) | SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL8262998 | 0.86 | SMN1; SMN2 (0.49) | SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL13314749 | 0.72 | SMN1; SMN2 (0.50) | SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL22258776 | 0.70 | ALDH1A1 (0.40) | SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL15120766 | 0.69 | HSD17B10 (0.68) | SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL1707707 | 0.68 | SMN1; SMN2 (0.75) | SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL12583021 | 0.66 | ATR (0.43) | SMN1; SMN2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL10073854 | 0.66 | HSD17B10 (0.64) | SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004270-A1 | 3,4-Disubstituted Pyrazoles as Cyclin Dependent Kinases (Cdk) or Aurora Kinase or Glycogen Synthase 3 (Gsk-3) Inhibitors | ASTEX THERAPEUTICS LIMITED (UK) | 2008-01-03 | — | — | US | disclosed |
| EP-1781653-A1 | 3,4-DISUBSTITUTED PYRAZOLES AS CYCLIN DEPENDENT KINASES (CDK) OR AURORA KINASE OR GLYCOGEN SYNTHASE 3 (GSK-3) INHIBITORS | Astex Therapeutics Limited (GB) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006003440-A1 | 3,4-DISUBSTITUTED PYRAZOLES AS CYCLIN DEPENDENT KINASES (CDK) OR AURORA KINASE OR GLYCOGEN SYNTHASE 3 (GSK-3) INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004270-A1 | 3,4-Disubstituted Pyrazoles as Cyclin Dependent Kinases (Cdk) or Aurora Kinase or Glycogen Synthase 3 (Gsk-3) Inhibitors | CDK3, CDK1, GSK3B | SMN1; SMN2 3622/4885KDM4E 674/4885ALDH1A1 4017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.